FIELD: medicine; phthisiology.
SUBSTANCE: invention can be used to reduce neurotoxicity occurring in patients with tuberculosis on using a complex of modern anti-tuberculosis drugs. Cytoflavin in 0.1 % starch gel in dose of 0.5 mg/kg is administered intragastrically to animals 10–15 minutes before the administration of the complex of anti-tuberculosis preparations. Complex of anti-tuberculosis preparations consists of moxifloxacin, linezolid, cycloserine and prothionamide.
EFFECT: method enables to reduce the manifestation of neurotoxic reactions in experimental animals caused by a complex of anti-tuberculosis preparations, which in turn improves horizontal motor activity, increases emotional status and exploratory activity of animals.
1 cl, 1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR MODELING DRUG NEUROTOXICITY USING COMPLEX OF ANTI-TUBERCULOSIS AND ANTIMICROBIAL DRUGS | 2022 |
|
RU2795524C1 |
METHOD FOR TREATMENT OF ADVERSE NEUROTOXIC RESPONSE CAUSED BY ANTITUBERCULOSIS PREPARATIONS | 2006 |
|
RU2312667C1 |
METHOD FOR SELECTING SHORTENED CHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PULMONARY TUBERCULOSIS | 2022 |
|
RU2805496C1 |
METHOD FOR TREATMENT OF PULMONARY TUBERCULOSIS MULTIPLE DRUG-RESISTANCE OF TUBERCULOSIS MYCOBACTERIA | 2018 |
|
RU2687743C1 |
ANTITUBECULOUS-CAUSED MEDICAMENTOUS POLYNEUROPATHY APPROACH | 2007 |
|
RU2353360C2 |
METHOD FOR REDUCING ISONIAZID NEUROTOXICITY EXPERIMENTALLY | 2014 |
|
RU2574027C1 |
METHOD FOR SIMULATING TOXIC HEART INVOLVEMENT IN RATS | 2019 |
|
RU2726926C1 |
METHOD FOR PREVENTION OF COMPLICATIONS INDUCED BY ISONIAZID | 2015 |
|
RU2597788C1 |
COMBINED THERAPY OF TUBERCULOSIS | 2009 |
|
RU2484819C2 |
METHOD FOR FORMING A CHEMOTHERAPY REGIMEN FOR PRIMARY INTRATHORACIC TUBERCULOSIS IN CHILDREN FROM TUBERCULOSIS INFECTION CENTERS | 2018 |
|
RU2704816C1 |
Authors
Dates
2024-06-13—Published
2023-07-10—Filed